CHRS - Coherus BioSciences, Inc.
| Previous Close | 14.80 |
| Open | 14.70 |
| Bid | 14.05 x 1000 |
| Ask | 17.30 x 4000 |
| Day's Range | 14.60 - 15.45 |
| 52 Week Range | 8.05 - 17.05 |
| Volume | 461,853 |
| Avg. Volume | 695,882 |
| Market Cap | 1.008B |
| Beta | 3.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.71 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.67 |
Markit•11 days agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is very weak relative to the trend shown over the past year.
- GlobeNewswire•25 days ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., May 25, 2018-- Coherus BioSciences, Inc., today announced that effective May 23, 2018, the compensation committee of the company’ s board of directors granted 4 new employees options ...
- GlobeNewswire•27 days ago
Coherus Prices Public Offering of Common Stock
Coherus BioSciences, Inc. (CHRS) today announced the pricing of its underwritten public offering of 5,172,413 shares of its common stock at a price to the public of $14.50 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 775,861 shares of its common stock at the public offering price, less the underwriting discount.
- GlobeNewswire•28 days ago
Coherus Announces Proposed Public Offering of Common Stock
Coherus BioSciences, Inc. (CHRS), today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of its common stock at the public offering price, less the underwriting discount.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CHRS earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Coherus BioSciences Inc Earnings Call
- ACCESSWIRE•last month
Blog Exposure - Xenon Announced Presentation of Positive XEN1101 TMS Pharmacodynamic Phase-1 Data at 14th Eilat Conference
LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Xenon Pharma Inc. (NASDAQ: XENE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=XENE as the Company's latest news hit the wire. On May 15, 2018, the Company announced that it has presented positive interim data from its ongoing XEN1101 Phase-1 clinical trial in a podium presentation at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (Eilat) held in Madrid, Spain. Active-Investors.com is currently working on the research report for Coherus BioSciences, Inc. (NASDAQ: CHRS), which also belongs to the Healthcare sector as the Company Xenon Pharma.
- GlobeNewswire•last month
U.S. Food and Drug Administration Accepts and Acknowledges Coherus BioSciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) for Review
Coherus BioSciences, Inc. (CHRS), today announced the U.S. Food and Drug Administration (FDA) has accepted and acknowledged for review the re-submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate. In the communication, FDA indicated that they consider the resubmission a complete response to their June 9, 2017 action letter. FDA provided a biosimilar user fee act (BSUFA) action date of November 3, 2018.
- Associated Press•last month
Coherus BioSciences: 1Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of 74 cents. Coherus BioSciences shares have risen 70 percent since the beginning of the year. In the final minutes of ...
- GlobeNewswire•last month
Coherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial Results
REDWOOD CITY, Calif., May 10, 2018-- Coherus BioSciences, Inc., today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2018.. First Quarter 2018 Corporate Highlights ...
- GlobeNewswire•last month
Coherus BioSciences Appoints Samuel Nussbaum, M.D. to Board of Directors
“We are thrilled to have a health care policy and payer expert of Dr. Nussbaum’s stature join the Coherus Board of Directors. Recent introductions of therapeutic biologics and biosimilars to the U.S. market, have highlighted the importance of a robust market access strategy and execution. Dr. Nussbaum’s distinguished career, experience, and leadership will make significant contributions to our efforts to deliver much needed treatments to patients and savings to the health care system,” said Denny Lanfear, Chairman, President and CEO of Coherus.
Markit•last monthSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GlobeNewswire•2 months ago
Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
REDWOOD CITY, Calif., May 03, 2018-- Coherus BioSciences, Inc., today announced the re-submission of its biologics license application for CHS-1701, a pegfilgrastim biosimilar candidate, to the U.S. FDA ...
- GlobeNewswire•2 months ago
Coherus BioSciences Management to Present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada
REDWOOD CITY, Calif., May 01, 2018-- Coherus BioSciences, Inc. today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, ...
- GlobeNewswire•2 months ago
Coherus BioSciences to Report First Quarter 2018 Financial Results on May 10th
REDWOOD CITY, Calif., April 24, 2018-- Coherus BioSciences, Inc., today announced that its first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018. Starting at ...
- GlobeNewswire•2 months ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., April 19, 2018-- Coherus BioSciences, Inc., today announced that effective April 19, 2018, the compensation committee of the company’ s board of directors granted 9 new employees ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
Coherus BioSciences Inc NASDAQ NMS:CHRS
- GlobeNewswire•3 months ago
Coherus BioSciences Management to Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco
REDWOOD CITY, Calif., April 02, 2018-- Coherus BioSciences, Inc. today announced that senior management will be presenting at the H.C. Wainwright Annual Life Sciences Conference on Tuesday, April 10, 2018 ...
- ACCESSWIRE•3 months ago
Free Post Earnings Research Report: Cambrex Achieved Record Quarterly Revenue; EPS Climbed 4%
Stock Monitor: Coherus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 16, 2018 / Active-Investors.com has just released a free earnings report on Cambrex Corp. (NYSE: CBM ). If you ...
- Motley Fool•3 months ago
Why II-VI, Coherus Biosciences, and El Pollo Loco Holdings Jumped Today
On a day the indexes advanced, these stocks saw outsize gains. Here's why.
- Investor's Business Daily•3 months ago
How This Small-Cap Biotech Plans To Chip Away At Amgen's Biggest Drugs
Coherus could begin chipping away at Amgen's second biggest moneymaker as soon as the second half of 2018.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of CHRS earnings conference call or presentation 8-Mar-18 9:30pm GMT
Q4 2017 Coherus BioSciences Inc Earnings Call
- Motley Fool•3 months ago
Why Coherus Biosciences Is Skyrocketing Today
Shares jump after management lays out a road map for the year ahead.
- Associated Press•3 months ago
Coherus BioSciences reports 4Q loss
The Redwood City, California-based company said it had a loss of 84 cents per share. For the year, the company reported that its loss widened to $238.2 million, or $4.48 per share. Revenue was reported ...
